Genetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer (2.04.151)
Blue Shield of California's medical policy 2.04.151, Genetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer, lists the tumor tissue and liquid biopsy tests it may consider medically necessary to select FDA-approved targeted treatments. The policy states an effective date of November 1, 2026, and its policy history for that date says the policy statement, guidelines and literature were updated, the title changed from Genetic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer, and a coding update was made. The policy refers to Appendix A for the policy statement changes from the previous version.